Giant Biogene Holding Co (HKSE:02367) Cash-to-Debt : 1,384.64 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Giant Biogene Holding Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 1,384.64.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Giant Biogene Holding Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Giant Biogene Holding Co's Cash-to-Debt or its related term are showing as below:

HKSE:02367' s Cash-to-Debt Range Over the Past 10 Years
Min: 849.49 Med: No Debt Max: No Debt
Current: 1384.64

During the past 5 years, Giant Biogene Holding Co's highest Cash to Debt Ratio was No Debt. The lowest was 849.49. And the median was No Debt.

HKSE:02367's Cash-to-Debt is ranked better than
94.99% of 1856 companies
in the Consumer Packaged Goods industry
Industry Median: 0.53 vs HKSE:02367: 1384.64

Giant Biogene Holding Co Cash-to-Debt Historical Data

The historical data trend for Giant Biogene Holding Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Giant Biogene Holding Co Cash-to-Debt Chart

Giant Biogene Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

849.49

1,384.64

Giant Biogene Holding Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			No Debt	N/A	849.49	1,317.40	1,384.64

Competitive Comparison of Giant Biogene Holding Co's Cash-to-Debt

For the Household & Personal Products subindustry, Giant Biogene Holding Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Giant Biogene Holding Co's Cash-to-Debt Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Giant Biogene Holding Co's Cash-to-Debt falls into.

Giant Biogene Holding Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Giant Biogene Holding Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4133.144	/	(1.71	+	1.275)
	=	1,384.64

Giant Biogene Holding Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4133.144	/	(1.71	+	1.275)
	=	1,384.64

Giant Biogene Holding Co (HKSE:02367) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Giant Biogene Holding Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Giant Biogene Holding Co (HKSE:02367) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN

Website

http://www.xajuzi.com

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines